
Bajolle Fanny

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2924712/publications.pdf Version: 2024-02-01



RAIOLLE FANNY

#	Article	IF	CITATIONS
1	Autoantibodies against type I IFNs in patients with life-threatening COVID-19. Science, 2020, 370, .	12.6	1,983
2	Inborn errors of type I IFN immunity in patients with life-threatening COVID-19. Science, 2020, 370, .	12.6	1,749
3	Acute Heart Failure in Multisystem Inflammatory Syndrome in Children in the Context of Global SARS-CoV-2 Pandemic. Circulation, 2020, 142, 429-436.	1.6	936
4	Kawasaki-like multisystem inflammatory syndrome in children during the covid-19 pandemic in Paris, France: prospective observational study. BMJ, The, 2020, 369, m2094.	6.0	835
5	Paediatric multisystem inflammatory syndrome temporally associated with SARS-CoV-2 mimicking Kawasaki disease (Kawa-COVID-19): a multicentre cohort. Annals of the Rheumatic Diseases, 2020, 79, 999-1006.	0.9	400
6	Association of Intravenous Immunoglobulins Plus Methylprednisolone vs Immunoglobulins Alone With Course of Fever in Multisystem Inflammatory Syndrome in Children. JAMA - Journal of the American Medical Association, 2021, 325, 855.	7.4	250
7	Polyclonal expansion of TCR Vβ 21.3 ⁺ CD4 ⁺ and CD8 ⁺ T cells is a hallmark of multisystem inflammatory syndrome in children. Science Immunology, 2021, 6, .	11.9	105
8	Multisystem Inflammatory Syndrome in Children: An International Survey. Pediatrics, 2021, 147, .	2.1	103
9	SARS-CoV-2–related MIS-C: A key to the viral and genetic causes of Kawasaki disease?. Journal of Experimental Medicine, 2021, 218, .	8.5	100
10	Autosomal Recessive Cardiomyopathy Presenting as Acute Myocarditis. Journal of the American College of Cardiology, 2017, 69, 1653-1665.	2.8	94
11	Rivaroxaban for treatment of pediatric venous thromboembolism. An Einsteinâ€Jr phase 3 doseâ€exposureâ€response evaluation. Journal of Thrombosis and Haemostasis, 2020, 18, 1672-1685.	3.8	52
12	Safety and efficacy of rivaroxaban in pediatric cerebral venous thrombosis (EINSTEIN-Jr CVT). Blood Advances, 2020, 4, 6250-6258.	5.2	49
13	Safety and efficacy of anticoagulant therapy in pediatric catheter-related venous thrombosis (EINSTEIN-Jr CVC-VTE). Blood Advances, 2020, 4, 4632-4639.	5.2	35
14	Distinctive Features of Kawasaki Disease Following SARS-CoV-2 Infection: a Controlled Study in Paris, France. Journal of Clinical Immunology, 2021, 41, 526-535.	3.8	29
15	Common Genetic Variants Contribute to Risk of Transposition of the Great Arteries. Circulation Research, 2022, 130, 166-180.	4.5	15
16	<xhtml:span xml:lang="en" xmlns:xhtml="http://www.w3.org/1999/xhtml">Association between SARS-CoV-2 infection and Kawasaki-like multisystem inflammatory syndrome: a retrospective matched case–control study, Paris, France, April to May 2020</xhtml:span> . Eurosurveillance, 2020, 25, .	7.0	9
17	Transcatheter patent arterial duct closure in premature infants: A new technique to ease access to the patent arterial duct, with particular benefit for the tricuspid valve. Archives of Cardiovascular Diseases, 2021, 114, 482-489.	1.6	6
18	Spontaneous Closure of the Arterial Duct after Transcatheter Closure Attempt in Preterm Infants. Children, 2021, 8, 1138.	1.5	4

#	Article	IF	CITATIONS
19	Position paper concerning the competence, performance and environment required for the practice of ablation in children and in congenital heart disease. Archives of Cardiovascular Diseases, 2020, 113, 492-502.	1.6	3
20	Multifactorial origin of pulmonary hypertension in a child with congenital heart disease, Down syndrome, and <i>BMPRâ€2</i> mutation. Pulmonary Circulation, 2021, 11, 1-3.	1.7	1